Are Peptides Legal in Ohio? (2026)

By the Peptide Bureau Research Team Regulation Reviewed by the Peptide Bureau Research Team on 28 September 2026

Not legal advice. This page summarises public statutes, board statements and enforcement records for Ohio as of 28 September 2026, for general information. It is not a legal opinion. Laws change; check the linked sources or a licensed Ohio attorney before relying on anything here. Compounds are discussed in a research context only.

Short answer. There is no Ohio statute that bans buying or possessing research peptides as a category. Federal law does the regulating: selling an unapproved peptide for human use is a federal violation by the seller, and human growth hormone has its own federal statute. The Bureau found no peptide that Ohio has scheduled or banned on its own. The Ohio Board of Pharmacy has taken a position on compounded semaglutide or tirzepatide, which matters if you are looking at a clinic or telehealth prescription rather than a research vial. Ohio's licensing boards have also spoken to peptide prescribing by clinics and medspas, which is where state-level risk actually sits (details below). Verified against the sources listed at the bottom on 28 September 2026. Not legal advice.

Ohio at a glance

State controlled-substances law: Ohio Revised Code Chapter 3719 (Controlled Substances); schedules at ORC 3719.41 as amended by Board of Pharmacy rule (Ohio Adm. Code 4729:9-1-01 to 4729:9-1-05) (law.onecle.com)
Human growth hormone under state law: Not separately scheduled; the federal statute 21 U.S.C. § 333(e) applies (Ohio Adm. Code 4729:9-1-03 (Schedule III); ORC 3719.41) (law.cornell.edu)
Research peptides scheduled by the state: None found
Board of Pharmacy on compounded GLP-1s: The Board of Pharmacy's guidance Compounding of GLP-1 Drug Products in Ohio (17 July 2025) says that after the FDA removed semaglutide and tirzepatide from the shortage list, compounded copies are essentially copies and may only be made where the drug is commercially unavailable or the prescriber documents a significant difference for the individual patient, and that active ingredient must be bought from an Ohio-licensed drug distributor. A later Board compliance alert (reported April 2026) says retatrutide is not FDA approved, semaglutide and BPC-157 cannot currently be compounded, and the Board has revoked or suspended several medspa terminal distributor licences for buying from unlicensed sellers or using research-use-only products. The Board's own PDFs block automated fetches, so both are confirmed through law-firm summaries (2025-07-17) (foley.com)
Medical board on peptide prescribing: No State Medical Board statement on research peptides or BPC-157 was found; Ohio's peptide positions come from the Board of Pharmacy, whose compliance material says BPC-157 cannot be compounded and lists buying research-use-only or unlicensed-source peptides among the common prescriber clinic and medspa violations that cost licences (2026-04) (bmdllc.com)
GLP-1 by telehealth: Yes. ORC 4743.09 authorises telehealth by physicians and other prescribers, and Medical Board rule 4731-11-09 requires an in-person examination of a new patient only before prescribing a Schedule II controlled substance; semaglutide and tirzepatide are non-controlled, so no in-person rule applies, though the prescriber must meet the standard of care. No express Ohio ban on questionnaire-only prescribing was found. (law.cornell.edu)
State-level enforcement, 2023 to 2026: 3 actions found
Last verified: 28 September 2026, confidence medium

The federal rules that apply in Ohio, as everywhere

Federal law is the same in every state, and it is where almost all of the legal weight sits. Under the Federal Food, Drug, and Cosmetic Act a product intended to treat a condition or change how the body works is a drug, and an unapproved new drug cannot be introduced into interstate commerce. That rule binds the seller, not the buyer. The FDA's 2026 warning letters to research-peptide vendors say the same thing eleven times over: a "research use only" label does not help when the website, the bundled bacteriostatic water or a dosing calculator shows the product is meant for human use. The Bureau's enforcement tracker lists every letter, case and lawsuit with its source.

Three federal points matter for a reader in Ohio:

Human growth hormone is the exception. 21 U.S.C. § 333(e) makes it a federal offence to distribute or possess somatropin for any use not approved by the Secretary of HHS. That statute covers HGH itself, not the secretagogues (sermorelin, ipamorelin, CJC-1295) that prompt the body's own release.
Compounding is a separate track. A licensed pharmacy may only compound from bulk substances on the FDA's 503A list. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon were moved to Category 2 in September 2023, removed from it in April 2026, and recommended for the list by the FDA's advisory committee on 23 and 24 July 2026. No rule has followed as of September 2026, so they still cannot be legally compounded anywhere, including Ohio. The PCAC vote page has every tally.
GLP-1 compounding is closing, not opening. The FDA has declared the semaglutide and tirzepatide shortages over, proposed in April 2026 to keep both off the 503B bulks list, and sent batches of letters to telehealth sellers in March and June 2026. Vials sold as "GLP-1 S" or "GLP-3 R" for research are unapproved new drugs in the FDA's view wherever the buyer lives.

What Ohio law adds

Ohio's controlled-substances law (Ohio Revised Code Chapter 3719 (Controlled Substances); schedules at ORC 3719.41 as amended by Board of Pharmacy rule (Ohio Adm. Code 4729:9-1-01 to 4729:9-1-05)) decides whether possessing a compound is a state offence. Peptides only become a state-law problem if they appear in those schedules or in a specific state ban. (law.onecle.com)

The Bureau found no research peptide (BPC-157, TB-500, ipamorelin, sermorelin, semaglutide, tirzepatide, retatrutide or the others covered on this site) on Ohio's schedules or in a Ohio-specific ban as of September 2026. That is the position in most states.

Human growth hormone

Ohio's Schedule III, including its anabolic steroid section, does not list human growth hormone, somatropin, hCG or any peptide. Separately, State Medical Board rule 4731-11-03(A)(1) bars physicians from prescribing growth hormone, testosterone or analogs to enhance athletic ability. (Ohio Adm. Code 4729:9-1-03 (Schedule III); ORC 3719.41) (law.cornell.edu)

Compounded semaglutide and tirzepatide

2025-07-17. The Board of Pharmacy's guidance Compounding of GLP-1 Drug Products in Ohio (17 July 2025) says that after the FDA removed semaglutide and tirzepatide from the shortage list, compounded copies are essentially copies and may only be made where the drug is commercially unavailable or the prescriber documents a significant difference for the individual patient, and that active ingredient must be bought from an Ohio-licensed drug distributor. A later Board compliance alert (reported April 2026) says retatrutide is not FDA approved, semaglutide and BPC-157 cannot currently be compounded, and the Board has revoked or suspended several medspa terminal distributor licences for buying from unlicensed sellers or using research-use-only products. The Board's own PDFs block automated fetches, so both are confirmed through law-firm summaries. (foley.com)

This is about licensed pharmacies and prescriptions. It does not make a research vial legal or illegal; those sit under the federal unapproved-drug rules described above.

Clinics, medspas and prescribers

2026-04. No State Medical Board statement on research peptides or BPC-157 was found; Ohio's peptide positions come from the Board of Pharmacy, whose compliance material says BPC-157 cannot be compounded and lists buying research-use-only or unlicensed-source peptides among the common prescriber clinic and medspa violations that cost licences. (bmdllc.com)

Buying, possessing and using research peptides in Ohio

Possessing an unscheduled research peptide is not a controlled-substance offence in Ohio; ORC 2925.11(A) reaches only scheduled drugs, so it would apply to a peptide only if Ohio scheduled it, and the federal rules bind the seller. (law.onecle.com)

Ordering from a vendor in another state. Almost every research-peptide order into Ohio is interstate commerce, which is exactly what the FDCA governs. The risk sits with the vendor: the FDA's letters name the seller, and Eli Lilly said in August 2026 it had referred more than 200 sellers to the FDA, the DOJ, state attorneys general and licensing boards. Connecticut's attorney general has already used state consumer-protection law against a "research grade" GLP-1 seller (2025), which is the template other states can copy. The Bureau's vendor scorecard notes which vendors publish batch testing; none of the scored vendors appears in the tracker as of September 2026.

GLP-1 drugs by prescription. Yes. ORC 4743.09 authorises telehealth by physicians and other prescribers, and Medical Board rule 4731-11-09 requires an in-person examination of a new patient only before prescribing a Schedule II controlled substance; semaglutide and tirzepatide are non-controlled, so no in-person rule applies, though the prescriber must meet the standard of care. No express Ohio ban on questionnaire-only prescribing was found. (law.cornell.edu) The branded pens are the only fully approved route; compounded versions are now on the wrong side of the FDA's shortage rules.

Sports and employment testing are not a Ohio law question. Growth hormone secretagogues and GHRH analogues are on the WADA Prohibited List everywhere; a standard workplace panel does not screen for peptides. The national legal guide covers both.

Not sure which of these you actually need?

Answer five questions about your goal, experience and budget and the Stack Builder shows you a matched research protocol on screen, with the compounds, cycle shape and vendor picks from the vendors we score.

Build your stack, 2 minutes

Enforcement in Ohio

2025-02-19. Attorney General Dave Yost signed the 38-state letter urging the FDA to act against counterfeit and research-only GLP-1 sales. (naag.org)
2025-04-16. Attorney General Yost sent warning letters to 14 Ohio medspas for advertising compounded semaglutide and tirzepatide as FDA approved or equivalent to the brand drugs. (spectrumnews1.com)
2026-04-29. The Board of Pharmacy has revoked or suspended several medspa terminal distributor of dangerous drugs licences for purchasing from unlicensed sellers and using research-purposes-only, unapproved or foreign drugs, per a law-firm summary of the Board's compliance alert; individual orders were not opened. (bmdllc.com)

A warning letter, lawsuit or board complaint is an allegation by the body that issued it, not a court finding, unless the entry says otherwise.

Editor's note. The Board of Pharmacy's GLP-1 and peptide documents and the attorney general's April 2025 release are confirmed through secondary summaries because the state sites block automated fetches; an editor should open them directly. Ohio is one of the more active states against medspas using research-grade product.

Frequently asked questions

Is BPC-157 legal in Ohio?

Ohio has not scheduled BPC-157, so possessing it is not a Ohio offence. Federally it is an unapproved new drug: selling it for human use is a violation by the seller, and licensed pharmacies cannot compound it because it is not on the 503A bulks list, despite the advisory committee's July 2026 recommendation. Research vendors sell it under a research-use-only label, which the FDA's 2026 letters treat as no defence when the site shows human use.

Can I get semaglutide or tirzepatide by telehealth in Ohio?

Yes. ORC 4743.09 authorises telehealth by physicians and other prescribers, and Medical Board rule 4731-11-09 requires an in-person examination of a new patient only before prescribing a Schedule II controlled substance; semaglutide and tirzepatide are non-controlled, so no in-person rule applies, though the prescriber must meet the standard of care. No express Ohio ban on questionnaire-only prescribing was found. The Ohio Board of Pharmacy position on compounded versions: The Board of Pharmacy's guidance Compounding of GLP-1 Drug Products in Ohio (17 July 2025) says that after the FDA removed semaglutide and tirzepatide from the shortage list, compounded copies are essentially copies and may only be made where the drug is commercially unavailable or the prescriber documents a significant difference for the individual patient, and that active ingredient must be bought from an Ohio-licensed drug distributor. A later Board compliance alert (reported April 2026) says retatrutide is not FDA approved, semaglutide and BPC-157 cannot currently be compounded, and the Board has revoked or suspended several medspa terminal distributor licences for buying from unlicensed sellers or using research-use-only products. The Board's own PDFs block automated fetches, so both are confirmed through law-firm summaries.

Is HGH legal in Ohio?

Only with a valid prescription for an approved use. Ohio does not schedule it separately, but federal law, 21 U.S.C. section 333(e), makes distribution or possession for any non-approved use a federal offence. Sermorelin, ipamorelin and CJC-1295 are not HGH and fall under the general unapproved-drug rules instead.

Sources

Every Ohio fact above was checked against the linked source on 28 September 2026. If a statute or board position has changed, email [email protected] with the link and the page will be corrected and dated.